

**MANCHESTER
CANCER
RESEARCH
CENTRE**

A New Era in Comprehensive Cancer Research and Care

One in two people receive a cancer diagnosis during their lifetime. Improving survival rates demands a fully integrated approach that unites researchers, clinicians, and patients to turn breakthroughs in the lab into real-world impact.



The Christie is an Accredited Comprehensive Cancer Centre

Comprehensive Cancer Centre (CCC) status is awarded by the Organisation of European Cancer Institutes (OEI) to institutions that meet high standards in cancer care, research, and education.



The Christie was the first UK organisation to earn this accreditation in 2008. For its successful 2025 re-accreditation, The Christie partnered with the Manchester Cancer Research Centre (MCRC) to showcase the city's collaborative, interdisciplinary approach to cancer.

A Collaborative Cancer Ecosystem

The MCRC spans a cluster of specialised, purpose-built research facilities for proton therapy, cancer imaging, basic and discovery cancer sciences and cancer biomarker development; all located in close proximity to precision oncology provided at The Christie. Additional cancer diagnostics, surgery and early detection programmes exist at Manchester NHS Foundation Trust, and within community general practices. This strategic geo-spatial layout fosters collaboration and accelerates the translation of research discoveries amongst 3 million people.



The Hallmarks of an International Comprehensive Cancer Centre

To achieve CCC status, institutions must demonstrate national and international research collaborations, a strong clinical trials infrastructure, and leading postgraduate and professional education programmes. For us, these hallmarks are more than requirements, they are the foundations of our future success. We apply these principles within diverse communities in Manchester and across the globe, exemplified by testing Manchester's mobile cancer early detection programme within Sub-Saharan Africa, to detect and cure lethal oesophageal cancer.

.....

The Impact of a CCC in Manchester and the UK

Holding CCC accreditation ensures continual innovations in research, education and care – driving improved survival rates and quality of life for cancer patients.

CCC accreditation enables:

- International benchmarking against 40+ other CCCs using similar, exacting international criteria
 - A rigorous peer review which allows us to measure ourselves against the highest global standards and drive continuous improvement
 - Global recognition that attracts talent, funding, and international partnerships
 - Patient access to novel clinical trials and cutting-edge treatments
 - Aligning world-leading impact stories for internal and external communications, philanthropy, and Research Excellence Awards
-

A Model for Integrated Cancer Research and Care

The Manchester Cancer Research Centre (MCRC) partners with the Christie Comprehensive Cancer Centre in transforming cancer outcomes for all. This integrated approach brings together world-leading scientists, clinicians, and educators to ensure every discovery moves swiftly from the lab to the patient's bedside.

What is the Manchester Cancer Research Centre?

The MCRC is a strategic partnership between:



The University of Manchester

World-leading interdisciplinary academic research and home of the NIHR Biomedical Research Centre.



The Christie NHS Foundation Trust

One of Europe's leading cancer centres and first in the UK to gain Comprehensive Cancer Centre accreditation.



Cancer Research UK

Supporting the CRUK Manchester Institute, Manchester Centre, and National Biomarker Centre, as well as ACED, RadNet, and Clinical Academic Training Awards.

This partnership also includes associate institutes, trusts, and funding bodies – driving major success in securing grants and advancing pioneering research and clinical innovation.

International Collaboration

CCC accreditation reinforces The Christie's and MCRC's position as a globally recognised leader in cancer research and care, driving high-impact international collaboration.

The newly established C8 Consortium – bringing together eight of the world's leading research-driven CCCs – advances translational cancer research and enables benchmarking against other top centres, fostering continuous improvement.

Princess Margaret
Cancer Centre
Toronto, Canada

MCRC and
The Christie
Manchester, UK

Institut Curie
Paris, France

National
Cancer Center
Tokyo, Japan

MD Anderson
Cancer Center
Texas, USA

Dana-Farber
Cancer Institute
Boston, USA

Cancer Biology
Research Center
Tel Aviv, Israel

Peter MacCallum
Cancer Centre
Melbourne, Australia



Clinical Trials in a Digital World

The Christie runs over 750 cutting-edge clinical trials each year, with many being Phase I (new drugs or technologies) designed by our scientists or in collaboration with Pharma. Importantly, our patients help shape these trials through interactions with our researchers. Our digital outcomes unit also measures cancer survival and patient reported side-effects to determine future standards of care.

“ I'm pleased to take part in research. If we don't try new treatments, then we'll not get the answers and make the medical advancements we need. **”**

Jan Smith, who recently took part in a clinical trial focused on improving outcomes for patients with inoperable or advanced melanoma.

Our Next-Gen Leaders

Through the newly re-branded Christie Institute for Cancer Education, staff receive best practice training and share innovations globally, ensuring patients in Manchester and around the globe benefit from the latest knowledge in cancer treatment and care.

The MCRC also offers a range of cancer-focused training programmes with a focus on next-gen research leadership. This includes Cancer Research UK-funded PhD programmes that provide state-of-the-art facilities and expert mentorship to conduct the best research in a rapidly evolving digital and data-driven world.




An Exciting Future for our World Leading Research Co-created With Our Patients

The MCRC and Christie Comprehensive Cancer Centre are at the forefront of a new molecular and digital era in cancer research and care.

Our unique cancer ecosystem, powerful international partnerships, research co-creation with our patients and CCC accreditation places us among the global leads that will shape the future of oncology.

Our patients will work closely with us to achieve faster access to state-of-the-art and practice-changing innovations, a swift translation of discoveries into the NHS, and the use of AI in understanding individual cancer risk assessment and response to our novel treatments.

Our Cancer Team Science approach ensures that every advance in our research leads to a real change at the bedside and added hope for our patients.



Programme Numbers at a Glance

60K

people cared for at
The Christie each year

£150M

in active
research grants

230K

patient samples
biobanked for research

100K+

chemotherapy and
immunotherapy treatments
delivered in 2024-2025

No. 1

The only UK centre with both
clinical and experimental
proton beam therapy

300+

next-gen cancer
trainees

750+

clinical trials and
studies currently active
at The Christie

100K+

treatment sessions of
advanced radiotherapy
delivered in 2024-2025

Learn more about the Christie Comprehensive
Cancer Centre and the MCRC:

www.mcrc.manchester.ac.uk/ccc

